Michelle A. Ochs Kinney
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Michelle A. Ochs Kinney has a total of 160 co-authors. Here are the top co-authors by number of shared publications:
- Carlos B. Mantilla
Mayo Clinic
4 shared publications Darrell R. Schroeder
Mayo Clinic, Rochester, MN, USA
3 shared publicationsMelissa A. Passe
Department of Anesthesiology, Anesthesia Clinical Research Unit, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
3 shared publicationsAndrew C. Hanson
Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA
2 shared publicationsBradly J. Narr
2 shared publications- Darrell R. Schroeder
Mayo Clinic
2 shared publications
Latest Publications
- Open Access
- 11 March 2024
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 24 (2) , 395-400
Sugammadex and urinary retention after hysterectomy: A propensity-matched cohort study
Postoperative urinary retention (POUR) is a well-known complication after gynecologic surgery. Our objective was to investigate whether the choice of pharmacologic agent for reversing neuromuscular blockade at the end of a hysterectomy is a risk factor for POUR. Among adult patients undergoing hysterectomy with general anesthesia from 2012 to 2017, those who received aminosteroid nondepolarizing neuromuscular agents followed by pharmacologic reversal were identified, and electronic health records were reviewed. The cohort was dichotomized into two groups by reversal agent: 1) sugammadex and 2) neostigmine with glycopyrrolate. The primary outcome, POUR, was defined as unplanned postoperative bladder recatheterization. A propensity-adjusted analysis was performed to investigate the association between POUR and reversal agent by using inverse probability of treatment weighting to adjust for potential confounders. We identified 1,974 patients, of whom 1,586 (80.3%) received neostigmine-glycopyrrolate and 388 (19.7%) received sugammadex for reversal of neuromuscular blockade. The frequency of POUR was 24.8% (393/1,586) after reversal with neostigmine-glycopyrrolate and 18.3% (71/388) with sugammadex. Results from the propensity-adjusted analysis showed that sugammadex was associated with a lower POUR risk than neostigmine-glycopyrrolate (odds ratio 0.53, 95% confidence interval [CI] 0.37 - 0.76, P < 0.001). A post hoc analysis of sugammadex recipients who received glycopyrrolate for another indication showed a higher POUR risk than among those who did not receive glycopyrrolate (odds ratio 1.86, 95% CI 1.07 - 3.22, P = 0.03). Use of sugammadex to reverse aminosteroid neuromuscular blocking agents is associated with decreased risk of POUR after hysterectomy. A potential mechanism is the omission of glycopyrrolate, which is coadministered with neostigmine to mitigate unwanted cholinergic effects.
- 11 March 2024
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 24 (2) , 395-400
Open AccessSugammadex and urinary retention after hysterectomy: A propensity-matched cohort study
Postoperative urinary retention (POUR) is a well-known complication after gynecologic surgery. Our objective was to investigate whether the choice of pharmacologic agent for reversing neuromuscular blockade at the end of a hysterectomy is a risk factor for POUR. Among adult patients undergoing hysterectomy with general anesthesia from 2012 to 2017, those who received aminosteroid nondepolarizing neuromuscular agents followed by pharmacologic reversal were identified, and electronic health records were reviewed. The cohort was dichotomized into two groups by reversal agent: 1) sugammadex and 2) neostigmine with glycopyrrolate. The primary outcome, POUR, was defined as unplanned postoperative bladder recatheterization. A propensity-adjusted analysis was performed to investigate the association between POUR and reversal agent by using inverse probability of treatment weighting to adjust for potential confounders. We identified 1,974 patients, of whom 1,586 (80.3%) received neostigmine-glycopyrrolate and 388 (19.7%) received sugammadex for reversal of neuromuscular blockade. The frequency of POUR was 24.8% (393/1,586) after reversal with neostigmine-glycopyrrolate and 18.3% (71/388) with sugammadex. Results from the propensity-adjusted analysis showed that sugammadex was associated with a lower POUR risk than neostigmine-glycopyrrolate (odds ratio 0.53, 95% confidence interval [CI] 0.37 - 0.76, P < 0.001). A post hoc analysis of sugammadex recipients who received glycopyrrolate for another indication showed a higher POUR risk than among those who did not receive glycopyrrolate (odds ratio 1.86, 95% CI 1.07 - 3.22, P = 0.03). Use of sugammadex to reverse aminosteroid neuromuscular blocking agents is associated with decreased risk of POUR after hysterectomy. A potential mechanism is the omission of glycopyrrolate, which is coadministered with neostigmine to mitigate unwanted cholinergic effects.
- Open Access
- 1 June 2021
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 21 (3) , 346-351
Postoperative respiratory depression after hysterectomy
To investigate if sex-specific physiologic characteristics could impact postoperative respiratory depression risks in women, we studied incidence and risk factors associated with postoperative respiratory depression in a gynecologic surgical cohort. Only hysterectomies performed under general anesthesia from 2012 to 2017 were included to minimize interprocedural variability. Respiratory depression was defined as episodes of apnea, hypopnea, hypoxemia, pain-sedation mismatch, unplanned positive airway pressure device application, or naloxone administration in the post-anesthesia care unit. Multivariable logistic regression was used to explore the association with clinical characteristics. From 1,974 hysterectomies, 253 had postoperative respiratory depression, yielding an incidence of 128 (95% confidence interval, 114–144) per 1,000 surgeries. Risk factors associated with respiratory depression were older age (odds ratio 1.22 [95% confidence interval 1.02–1.46] per decade increase, p = 0.03), lower body weight (0.77 [0.62–0.94] per 10 kg/m2, p = 0.01), and higher intraoperative opioid dose (1.05 [1.01–1.09] per 10 mg oral morphine equivalents, p = 0.01); while sugammadex use was associated with a reduced risk (0.48 [0.30–0.75], p = 0.002). Respiratory depression was not associated with increased hospital stay, postoperative complications, or mortality. Postoperative respiratory depression risk in women increased with age, lower weight, and higher intraoperative opioids and decreased with sugammadex use; however, it was not associated with postoperative pulmonary complications.
- 1 June 2021
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 21 (3) , 346-351
Open AccessPostoperative respiratory depression after hysterectomy
To investigate if sex-specific physiologic characteristics could impact postoperative respiratory depression risks in women, we studied incidence and risk factors associated with postoperative respiratory depression in a gynecologic surgical cohort. Only hysterectomies performed under general anesthesia from 2012 to 2017 were included to minimize interprocedural variability. Respiratory depression was defined as episodes of apnea, hypopnea, hypoxemia, pain-sedation mismatch, unplanned positive airway pressure device application, or naloxone administration in the post-anesthesia care unit. Multivariable logistic regression was used to explore the association with clinical characteristics. From 1,974 hysterectomies, 253 had postoperative respiratory depression, yielding an incidence of 128 (95% confidence interval, 114–144) per 1,000 surgeries. Risk factors associated with respiratory depression were older age (odds ratio 1.22 [95% confidence interval 1.02–1.46] per decade increase, p = 0.03), lower body weight (0.77 [0.62–0.94] per 10 kg/m2, p = 0.01), and higher intraoperative opioid dose (1.05 [1.01–1.09] per 10 mg oral morphine equivalents, p = 0.01); while sugammadex use was associated with a reduced risk (0.48 [0.30–0.75], p = 0.002). Respiratory depression was not associated with increased hospital stay, postoperative complications, or mortality. Postoperative respiratory depression risk in women increased with age, lower weight, and higher intraoperative opioids and decreased with sugammadex use; however, it was not associated with postoperative pulmonary complications.
- 1 February 2021
- Vol. 89 (1) , 19-25
Examining Use of Low-Dose Ketamine Infusions During the Postoperative Period: A Retrospective Study Comparing Opioid-Tolerant and Nonopioid-Tolerant Patients.
Ketamine is a well-known anesthetic that has been used since the 1970s. Despite its ubiquitous use as a postoperative analgesic, no studies have described dosing differences between opioid-tolerant (OT) and nonopioid-tolerant (NOT) patients or determined optimal dosing. The primary aim of this study was to assess whether OT and NOT patients had significant differences in ketamine infusion dosing requirements. We also aimed to measure the overall incidence of psychotomimetic adverse effects associated with low-dose ketamine infusions. We hypothesized that NOT patients would have lower ketamine infusion dosing requirements and a higher incidence of psychotomimetic adverse effects compared with OT patients. We performed a retrospective chart review and showed that the percentages of OT and NOT patients experiencing psychotomimetic adverse effects were similar (15.5% vs 15.3%; P=.93) and that increasing age was the only factor associated with increased odds of experiencing a psychotomimetic adverse effect potentially associated with ketamine (odds ratio, 1.29 [95% CI, 1.11-1.50]; P=.001). Optimal subanesthetic ketamine infusion dosing could not be established, and further research in this area may be warranted.
- 1 February 2021
- Vol. 89 (1) , 19-25
Examining Use of Low-Dose Ketamine Infusions During the Postoperative Period: A Retrospective Study Comparing Opioid-Tolerant and Nonopioid-Tolerant Patients.
Ketamine is a well-known anesthetic that has been used since the 1970s. Despite its ubiquitous use as a postoperative analgesic, no studies have described dosing differences between opioid-tolerant (OT) and nonopioid-tolerant (NOT) patients or determined optimal dosing. The primary aim of this study was to assess whether OT and NOT patients had significant differences in ketamine infusion dosing requirements. We also aimed to measure the overall incidence of psychotomimetic adverse effects associated with low-dose ketamine infusions. We hypothesized that NOT patients would have lower ketamine infusion dosing requirements and a higher incidence of psychotomimetic adverse effects compared with OT patients. We performed a retrospective chart review and showed that the percentages of OT and NOT patients experiencing psychotomimetic adverse effects were similar (15.5% vs 15.3%; P=.93) and that increasing age was the only factor associated with increased odds of experiencing a psychotomimetic adverse effect potentially associated with ketamine (odds ratio, 1.29 [95% CI, 1.11-1.50]; P=.001). Optimal subanesthetic ketamine infusion dosing could not be established, and further research in this area may be warranted.
- 1 December 2018
- Published by Elsevier in Journal of Clinical Anesthesia
- Vol. 51, 93-96
Partial hepatic resections for metastatic neuroendocrine tumors: perioperative outcomes
- 1 December 2018
- Published by Elsevier in Journal of Clinical Anesthesia
- Vol. 51, 93-96
Partial hepatic resections for metastatic neuroendocrine tumors: perioperative outcomes
- Open Access
- 2 June 2016
- Published by Wiley in Pain Research and Treatment
- Vol. 2016, 1-6
Increased Risk of Postthoracotomy Pain Syndrome in Patients with Prolonged Hospitalization and Increased Postoperative Opioid Use
Background. Postthoracotomy pain syndrome (PTPS) is unfortunately very common following thoracotomy and results in decreased quality of life. The purpose of this retrospective study was to determine perioperative patient, surgical, and analgesic characteristics associated with the development of PTPS. Methods. Sixty-six patients who presented to the Mayo Clinic Rochester Pain Clinic were diagnosed with PTPS 2 months or more after thoracotomy with postoperative epidural analgesia. These patients were matched with sixty-six control patients who underwent thoracotomy with postoperative epidural analgesia and were never diagnosed with PTPS. Results. Median (IQR) hospital stay was significantly different between control patients (5 days (4, 6)) compared with PTPS patients (6 days (5, 8)), . The total opioid equivalent utilized in oral morphine equivalents in milligrams for the first three days postoperatively was significantly different between control patients and PTPS patients. The median (IQR) total opioid equivalent utilized was 237 (73, 508) for controls and 366 (116, 874) for PTPS patients (). Conclusion. Patients with a prolonged hospital stay after thoracotomy were at an increased risk of developing PTPS, and this is a novel finding. Patients who utilize higher oral morphine equivalents for the first 3 days were also at increased risk for PTPS.- 2 June 2016
- Published by Wiley in Pain Research and Treatment
- Vol. 2016, 1-6
Open AccessIncreased Risk of Postthoracotomy Pain Syndrome in Patients with Prolonged Hospitalization and Increased Postoperative Opioid Use
Background. Postthoracotomy pain syndrome (PTPS) is unfortunately very common following thoracotomy and results in decreased quality of life. The purpose of this retrospective study was to determine perioperative patient, surgical, and analgesic characteristics associated with the development of PTPS. Methods. Sixty-six patients who presented to the Mayo Clinic Rochester Pain Clinic were diagnosed with PTPS 2 months or more after thoracotomy with postoperative epidural analgesia. These patients were matched with sixty-six control patients who underwent thoracotomy with postoperative epidural analgesia and were never diagnosed with PTPS. Results. Median (IQR) hospital stay was significantly different between control patients (5 days (4, 6)) compared with PTPS patients (6 days (5, 8)), . The total opioid equivalent utilized in oral morphine equivalents in milligrams for the first three days postoperatively was significantly different between control patients and PTPS patients. The median (IQR) total opioid equivalent utilized was 237 (73, 508) for controls and 366 (116, 874) for PTPS patients (). Conclusion. Patients with a prolonged hospital stay after thoracotomy were at an increased risk of developing PTPS, and this is a novel finding. Patients who utilize higher oral morphine equivalents for the first 3 days were also at increased risk for PTPS. - Open Access
- 6 August 2012
- Published by Springer Nature in BMC Research Notes
- Vol. 5 (1) , 412
Emergency bedside cesarean delivery: lessons learned in teamwork and patient safety
Maternal cardiovascular and pulmonary events during labor and delivery may result in adverse maternal and fetal outcome. Potential etiologies include primary cardiac events, pulmonary embolism, eclampsia, maternal hemorrhage, and adverse medication events. Remifentanil patient-controlled analgesia is an alternative when conventional neuraxial analgesia for labor is contraindicated. Although remifentanil is a commonly used analgesic, its use for labor analgesia is not clearly defined.
- 6 August 2012
- Published by Springer Nature in BMC Research Notes
- Vol. 5 (1) , 412
Open AccessEmergency bedside cesarean delivery: lessons learned in teamwork and patient safety
Maternal cardiovascular and pulmonary events during labor and delivery may result in adverse maternal and fetal outcome. Potential etiologies include primary cardiac events, pulmonary embolism, eclampsia, maternal hemorrhage, and adverse medication events. Remifentanil patient-controlled analgesia is an alternative when conventional neuraxial analgesia for labor is contraindicated. Although remifentanil is a commonly used analgesic, its use for labor analgesia is not clearly defined.
- 1 April 2012
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 93 (4) , 1242-1247
Chronic Postthoracotomy Pain and Health-Related Quality of Life
- 1 April 2012
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 93 (4) , 1242-1247
Chronic Postthoracotomy Pain and Health-Related Quality of Life
- 16 June 2011
- Published by Wiley in Pain Practice
- Vol. 12 (3) , 175-183
Preoperative Gabapentin for Acute Post‐thoracotomy Analgesia: A Randomized, Double‐Blinded, Active Placebo‐Controlled Study
Background: The role of preoperative gabapentin in postoperative pain management is not clear, particularly in patients receiving regional blockade. Patients undergoing thoracotomy benefit from epidural analgesia but still may experience significant postoperative pain. We examined the effect of preoperative gabapentin in thoracotomy patients.Methods: Adults undergoing elective thoracotomy were enrolled in this prospective, randomized, double‐blinded, placebo‐controlled study, and randomly assigned to receive 600 mg gabapentin or active placebo (12.5 mg diphenhydramine) orally within 2 hours preoperatively. Standardized management included thoracic epidural infusion, intravenous patient‐controlled opioid analgesia, acetaminophen and ketorolac. Pain scores, opioid use and side effects were recorded for 48 hours. Pain was also assessed at 3 months.Results: One hundred twenty patients (63 placebo and 57 gabapentin) were studied. Pain scores did not significantly differ at any time point (P = 0.53). Parenteral and oral opioid consumption was not significantly different between groups on postoperative day 1 or 2 (P > 0.05 in both cases). The frequency of side effects such as nausea and vomiting or respiratory depression was not significantly different between groups, but gabapentin was associated with decreased frequency of pruritus requiring nalbuphine (14% gabapentin vs. 43% control group, P < 0.001). The frequency of patients experiencing pain at 3 months post‐thoracotomy was also comparable between groups (70% gabapentin vs. 66% placebo group, P = 0.72).Conclusions: A single preoperative oral dose of gabapentin (600 mg) did not reduce pain scores or opioid consumption following elective thoracotomy, and did not confer any analgesic benefit in the setting of effective multimodal analgesia that included thoracic epidural infusion.
- 16 June 2011
- Published by Wiley in Pain Practice
- Vol. 12 (3) , 175-183
Preoperative Gabapentin for Acute Post‐thoracotomy Analgesia: A Randomized, Double‐Blinded, Active Placebo‐Controlled Study
Background: The role of preoperative gabapentin in postoperative pain management is not clear, particularly in patients receiving regional blockade. Patients undergoing thoracotomy benefit from epidural analgesia but still may experience significant postoperative pain. We examined the effect of preoperative gabapentin in thoracotomy patients.Methods: Adults undergoing elective thoracotomy were enrolled in this prospective, randomized, double‐blinded, placebo‐controlled study, and randomly assigned to receive 600 mg gabapentin or active placebo (12.5 mg diphenhydramine) orally within 2 hours preoperatively. Standardized management included thoracic epidural infusion, intravenous patient‐controlled opioid analgesia, acetaminophen and ketorolac. Pain scores, opioid use and side effects were recorded for 48 hours. Pain was also assessed at 3 months.Results: One hundred twenty patients (63 placebo and 57 gabapentin) were studied. Pain scores did not significantly differ at any time point (P = 0.53). Parenteral and oral opioid consumption was not significantly different between groups on postoperative day 1 or 2 (P > 0.05 in both cases). The frequency of side effects such as nausea and vomiting or respiratory depression was not significantly different between groups, but gabapentin was associated with decreased frequency of pruritus requiring nalbuphine (14% gabapentin vs. 43% control group, P < 0.001). The frequency of patients experiencing pain at 3 months post‐thoracotomy was also comparable between groups (70% gabapentin vs. 66% placebo group, P = 0.72).Conclusions: A single preoperative oral dose of gabapentin (600 mg) did not reduce pain scores or opioid consumption following elective thoracotomy, and did not confer any analgesic benefit in the setting of effective multimodal analgesia that included thoracic epidural infusion.
- 2 June 2003
- Published by Wiley in Clinical Anatomy
- Vol. 16 (4) , 362-365
Prolonged facial hypesthesia resulting from greater occipital nerve block
- 2 June 2003
- Published by Wiley in Clinical Anatomy
- Vol. 16 (4) , 362-365
Prolonged facial hypesthesia resulting from greater occipital nerve block
- 1 June 2002
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 16 (3) , 359-369
Perioperative management of pheochromocytoma
- 1 June 2002
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 16 (3) , 359-369
Perioperative management of pheochromocytoma